Rivastigmine Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed rivastigmine for Alzheimer's or Parkinson's disease dementia may contact your office reporting difficulty filling their prescription. While rivastigmine is not currently listed on the FDA's official shortage database, localized pharmacy stock gaps — particularly for specific strengths and the transdermal patch — continue to create real-world access barriers. This guide summarizes the current availability situation and provides clinical guidance for managing affected patients.

Current Shortage Status (2026)

As of 2026, rivastigmine (generic capsule, oral solution, and generic transdermal patches) is not in a declared national FDA shortage. However, the following supply-side factors contribute to localized access problems:

Brand capsule discontinuation: The branded Exelon capsule is no longer available. Some pharmacies may not have fully transitioned to ordering the generic replacement.

Patch strength gaps: The 4.6 mg/24h (initial titration) and 13.3 mg/24h (high-dose) patch strengths are stocked less frequently than the 9.5 mg/24h maintenance dose.

Generic manufacturer variability: Multiple generic manufacturers means different formulations at different pharmacies. A pharmacy's wholesaler may intermittently supply a different manufacturer's product.

Increasing prevalence-driven demand: As the U.S. population ages, dementia prevalence — and hence demand for cholinesterase inhibitors — continues to rise.

Clinical Considerations When Patients Can't Access Rivastigmine

Abrupt discontinuation of rivastigmine can lead to rapid cognitive decline. The literature consistently supports the recommendation to restart at a lower dose after any significant interruption (typically more than 3 days for the capsule, or missing several patch replacements).

When a patient presents with an access problem, consider the following clinical pathways:

Pathway 1: Switch Between Rivastigmine Formulations

If one rivastigmine formulation is unavailable, switching between the oral capsule and the transdermal patch is feasible but requires dose recalculation. Key equivalences from the prescribing information:

Oral 6 mg/day (3 mg BID) → switch to 4.6 mg/24h patch (starting dose)

Oral 6–12 mg/day (3–6 mg BID) → switch to 9.5 mg/24h patch (maintenance dose)

The 9.5 mg/24h patch delivers comparable systemic exposure to the highest oral dose (12 mg/day) with significantly fewer GI side effects

For patients switching due to intolerable GI side effects from the oral form — not just supply issues — the patch is often the preferred long-term solution.

Pathway 2: Switch to Donepezil (Alzheimer's Disease)

For patients with Alzheimer's dementia who cannot access rivastigmine, donepezil is the most logical alternative. Efficacy is similar across clinical trials. Key prescribing notes for the switch:

Initiate donepezil at 5 mg once daily; titrate to 10 mg after 4–6 weeks if tolerated

Donepezil does not require twice-daily dosing — an advantage for adherence

Approved for all stages of Alzheimer's dementia (mild, moderate, and severe) — unlike rivastigmine oral, which is approved only for mild-to-moderate

Generic donepezil is very affordable and widely stocked

Pathway 3: Parkinson's Disease Dementia — Special Considerations

Rivastigmine has the only FDA approval specifically for dementia associated with Parkinson's disease (PDD). When rivastigmine is unavailable for PDD patients, the clinical options are more limited:

Donepezil (off-label): Supported by some clinical evidence for PDD, but lacks FDA approval for this indication

Memantine: Limited evidence for PDD specifically; occasionally used off-label; may be considered in moderate-to-severe stages

Galantamine: No FDA approval for PDD; not generally recommended

In practice, if a PDD patient cannot access rivastigmine, the most reasonable approach is to contact a neurologist or movement disorder specialist to collaboratively manage the interim period.

Titration Protocol After Medication Interruption

If a patient has missed more than 3 consecutive days of rivastigmine capsules (or has missed replacing patches for 3+ days), restarting at the full previous dose carries a high risk of cholinergic GI toxicity. The recommended approach:

Oral capsule: restart at 1.5 mg BID and re-titrate every 2 weeks as tolerated, up to the previous effective dose

Transdermal patch: restart at 4.6 mg/24h and re-titrate every 4 weeks as tolerated

How medfinder Can Help Your Patients

medfinder is a service that calls pharmacies on behalf of patients to locate in-stock medications. For dementia patients — and often their caregivers — navigating multiple pharmacy calls is a significant burden. Referring your patients to medfinder.com/providers can reduce that burden and help ensure continuity of therapy.

Additional Resources

Share with affected patients: Rivastigmine shortage update for patients (2026). For a prescriber-focused pharmacy locating guide, see how to help your patients find rivastigmine in stock.